FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

wasnington,	D.C. 20049	

**OMB APPROVAL** 3235-0287

0.5

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Estimated average burden hours per response: Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Brown Martin S JR					CU	2. Issuer Name <b>and</b> Ticker or Trading Symbol  CUMBERLAND PHARMACEUTICALS  INC CPIX									ck all app Direct	tionship of Reporting Po all applicable) Director		10% Owner	
(Last) 1600 WE	(Last) (First) (Middle) 1600 WEST END AVENUE, SUITE 1300					3. Date of Earliest Transaction (Month/Day/Year) 03/24/2023										Officer (give title below)		Other (specify below)	
(Street) NASHV	ILLE T	N 3	7203		4. If <i>I</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Ind Line) X	Form	or Joint/Group Filing (Check Applicable in filed by One Reporting Person in filed by More than One Reporting ison			
(City)	(S	tate) (Z	Zip)		Rule 10b5-1(c) Transaction Indication									uction or writt	ten pla	n that is inter	nded to		
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da				Exec		Deemed cution Date, ny nth/Day/Year)		3. Transaction Code (Instr. 8)  4. Securitie Disposed (5)		es Acquired (A) o Of (D) (Instr. 3, 4		) or 4 and		ties Fo cially (D I Following (I)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(D)		rice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock 03/24/						2023			A		1,000(1)	A	\   {	51.97	5	5,000		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any		ion Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		te	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		De Se (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
								Date Exercis	able	Expiration Date	Amoul or Number of Title Shares		er						

## **Explanation of Responses:**

1. Restricted stock award will vest 100% on March 24, 2024

## Remarks:

Martin S. Brown Jr. by /s/ John M. Hamm as attorney-in- 03/27/2023

fact

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.